Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Shares Outstanding (Weighted Average) (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Shares Outstanding (Weighted Average) for 8 consecutive years, with $31.2 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) changed N/A to $31.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $31.2 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $31.2 million at Actinium Pharmaceuticals, roughly flat from $31.2 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $31.2 million in Q1 2025, with the low at $18.4 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $25.9 million, with a median of $26.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) grew 25.44% in 2022, then increased 0.4% in 2025.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $20.6 million in 2021, then grew by 17.37% to $24.1 million in 2022, then increased by 10.2% to $26.6 million in 2023, then increased by 16.79% to $31.1 million in 2024, then rose by 0.4% to $31.2 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $31.2 million, $31.2 million, and $31.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.